- Commission reaches an agreement with Moderna to accelerate the delivery of its mRNA vaccine
- The U.S. and the EU expand cooperation for global action toward vaccinating the world
- Team Europe vaccine sharing: almost 100 million Johnson and Johnson doses to be donated by the end of 2021
- Commission approves new contract for a potential COVID-19 vaccine with Valneva
- European Health Union: green light for two new COVID-19 therapeutics
Figures on vaccination
- 1.29 billion doses delivered
- 81.2 %of the EU adult population fully vaccinated
Last updated: 27 January 2022. Source: Vaccines producers and ECDC data.
Information about vaccination in the EU
Securing safe and effective vaccines
The European Commission has been negotiating intensely to build a diversified portfolio of vaccines for EU citizens at fair prices. Contracts have been concluded with 8 promising vaccine developers, securing a portfolio of up to 4.2 billion doses.
Deliveries of vaccine doses to European Union countries have increased steadily since December 2020. Vaccination has gathered pace across the European Union.
By the end of 2021, close to 80% of the EU’s adult population was fully vaccinated. Meanwhile, the Commission has negotiated two additional contracts with pharmaceutical companies to secure more COVID-19 vaccines – for young people, for the EU’s international partners, for booster shots and to guard against new variants.
Effective and broad vaccination is the best strategy to overcome the pandemic. Based on current evidence, all vaccines authorised in the EU are highly protective against hospitalisation, severe disease and death, with an effectiveness in the general population of over 80%.
There is a clear link between the level of vaccination and hospitalisation and death rates: the higher the vaccination rate, the lower the risk of being hospitalised or dying.
Increasing vaccination rates of all eligible groups, particularly of the elderly, the vulnerable and healthcare workers across the EU, therefore remains the first priority to control the spread of COVID-19.
Evidence shows booster doses offer a significant increase in protection against infection and severe diseases. The ECDC therefore recommends a booster for adults, prioritising those over 40, at least 6 months after primary vaccination.
To secure enough doses, the Commission has also worked closely with the industry to step up vaccine manufacturing capacity in the EU. By the end of 2021, manufacturing capacity in Europe is expected to reach 300 million doses per month.
At the same time, the Commission has started work to anticipate and tackle new variants of the virus and to rapidly develop and produce vaccines effective against those variants on a large-scale.
This is why the European Commission has launched HERA, the European Health Emergency preparedness and Response Authority. HERA will anticipate threats and potential health crises, through intelligence gathering and building the necessary response capacities to enable rapid response to health emergencies.
EU’s vaccine portfolio
The Commission has so far given 5 conditional marketing authorisations for the vaccines developed by BioNTech and Pfizer, Moderna, AstraZeneca, Janssen Pharmaceutica NV, and Novavax respectively, following the European Medicines Agency’s (EMA) positive assessment of their safety and efficacy. Several other vaccines are at different stages of assessment by the EMA.
- up to 4.2 billion doses
Type of vaccine
Number of doses
(needed per person)
Number of doses
|BioNTech and Pfizer||mRNA||2 doses||2.4 billion*||Approved|
|Moderna||mRNA||2 doses||460 million||Approved|
|AstraZeneca||adenovirus||2 doses||400 million||Approved|
|Johnson & Johnson/Janssen Pharmaceuticals||adenovirus||1 dose||400 million||Approved|
|Sanofi-GSK||protein||2 doses||300 million||Under EMA rolling review|
|Novavax||protein||2 doses||200 million**||Approved|
|Valneva||inactivated virus vaccine||60 million||In development|
*option to purchase 900 million doses, **option to purchase 100 million doses
The European Medicines Agency publishes safety updates for the COVID-19 vaccines authorised in the EU. EMA releases a monthly update for each authorised COVID-19 vaccine.
The safety updates summarise the data that have become available since the vaccine's authorisation. They also indicate whether any safety information requires further investigation.
For more information, visit the EMA webpage.
Check the facts
Disinformation on the coronavirus is thriving. It is important that you get updated information from authoritative sources only. We suggest that you follow the advice of your public health authorities, and the websites of relevant EU and international organisations: the European Centre for Disease Control (ECDC ) and the World Health Organization (WHO).
You can also help by not sharing unverified information that comes from dubious sources.
The EU vaccine strategy
With the EU Vaccines Strategy, the EU is supporting efforts to accelerate the development and availability of safe and effective vaccines in a timeframe of less than one year for most vaccines.
The Commission entered into advanced purchase agreements with individual vaccine producers on behalf of the Member States, and secured more than 4.2 billion doses of vaccines for European citizens and for countries around the world where vaccines are less available.
Interview about vaccination with Ms Marie-Francoise Fuchs
How do vaccines work?